Patheon to expand Manati Puerto Rico facility for high potency production
Global provider of drug development and manufacturing services Patheon, says it will expand the Manati, Puerto Rico facility to add a dedicated high potency and controlled substance manufacturing area.
Global provider of drug development and manufacturing services Patheon, says it will expand the Manati, Puerto Rico facility to add a dedicated high potency and controlled substance manufacturing area.
Patheon will invest a total of US$2.8m in this new 3,386 ft2 area that will include three manufacturing suites, air lock containment areas, and humidity controlled air systems.
The three manufacturing suites will enable Patheon to combine in one manufacturing area technology transfer, bulk production, bulk packaging, and storage. The production area will have capacity for high potency (containment down to 1 µg/m3 OEL) and humidity controlled solid dosage form products.
The construction project is currently in a fast track mode with completion expected, based on current activity, by the end of September 2008.
Patheon has been contracted by one customer to utilise the suites and the expansion will also provide substantial capacity to serve additional high-potency projects.